Search
Human umbilical cord blood mononuclear cell-conditioned medium
go.drugbank.com/drugs/DB15724ExperimentalThus, the media in which they are cultured is believed to also have therapeutic potential. … When HUCBCs secrete growth factors and anti-inflammatory cytokines, they are thought to reduce inflammation and associated damage.
Fleroxacin
go.drugbank.com/drugs/DB04576ExperimentalFleroxacin is not an inhibitor of CYP1A2.[A39048]
BMS-986141
go.drugbank.com/drugs/DB14942InvestigationalBMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
V116517
go.drugbank.com/drugs/DB16060InvestigationalV116517 is under investigation in clinical trial NCT01688947 (Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)).
ARC183
go.drugbank.com/drugs/DB05124ExperimentalARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity … The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid
CX157
go.drugbank.com/drugs/DB05205InvestigationalCX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous
MP4
go.drugbank.com/drugs/DB05313InvestigationalMP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. … It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.
MW33
go.drugbank.com/drugs/DB16358ExperimentalMW33 is a recombinant fully human antibody to SARS-CoV-2. … [L27411] This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
Elsamitrucin
go.drugbank.com/drugs/DB05129InvestigationalThe cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)
Ganulameran
go.drugbank.com/drugs/DB16442InvestigationalThe BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.